NIZ-985 is under clinical development by Novartis and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData, Phase I drugs for Metastatic Prostate Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NIZ-985’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NIZ-985 is under development for the treatment of metastatic cancers like prostate cancer, cutaneous melanoma, solid tumor, NSCL and lymphoma. It is a recombinant protein composed of IL-15 and IL-15 receptor alpha heterodimer. The drug candidate is administered through subcutaneous route. It acts by targeting IL2RB and IL2RG. It was also under development for ocular melanoma.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of NIZ-985’s drug-specific PTSR and LoA scores, buy the report here.